Gastric inhibitory polypeptide API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Gastric inhibitory polypeptide API 100040-31-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Gastric inhibitory polypeptide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Gastric inhibitory polypeptide
- Synonyms:
- GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE
- Cas Number:
- 100040-31-1
- DrugBank number:
- DB15217
- Unique Ingredient Identifier:
- 1O4H75S7H2
General Description:
Gastric inhibitory polypeptide, identified by CAS number 100040-31-1, is a notable compound with significant therapeutic applications. Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).
Categories:
Gastric inhibitory polypeptide is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Gastrointestinal Agents, Gastrointestinal Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Incretins, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Proteins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Gastric inhibitory polypeptide is a type of Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
